CLINICAL TRIALS PROFILE FOR CORTISONE ACETATE
✉ Email this page to a colleague
All Clinical Trials for cortisone acetate
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00489840 ↗ | Treatment of Chronic Central Serous Chorioretinopathy With Open-Label Anecortave Acetate | Completed | Alcon Research | Phase 1/Phase 2 | 2007-05-01 | Investigation to evaluate Anecortave Acetate in the treatment of chronic central serous chorioretinopathy |
| NCT00489840 ↗ | Treatment of Chronic Central Serous Chorioretinopathy With Open-Label Anecortave Acetate | Completed | LuEsther T. Mertz Retinal Research Center | Phase 1/Phase 2 | 2007-05-01 | Investigation to evaluate Anecortave Acetate in the treatment of chronic central serous chorioretinopathy |
| NCT00489840 ↗ | Treatment of Chronic Central Serous Chorioretinopathy With Open-Label Anecortave Acetate | Completed | Manhattan Eye, Ear & Throat Hospital | Phase 1/Phase 2 | 2007-05-01 | Investigation to evaluate Anecortave Acetate in the treatment of chronic central serous chorioretinopathy |
| NCT00915343 ↗ | Once-daily Oral Modified Release Hydrocortisone in Patients With Adrenal Insufficiency | Completed | Shire | Phase 2/Phase 3 | 2007-08-21 | This is a randomised, controlled, open, two-armed, two-period cross-over, multi-centre phase II/III study to assess the safety, tolerability and pharmacokinetics of once-daily oral modified-release hydrocortisone in comparison to conventional thrice-daily oral hydrocortisone tablets in patients with adrenal insufficiency |
| NCT01771328 ↗ | Continuous Subcutaneous Hydrocortisone Infusion in Congenital Adrenal Hyperplasia | Unknown status | Haukeland University Hospital | Phase 2 | 2013-02-01 | The conventional glucocorticoid replacement therapy in congenital adrenal hyperplasia (CAH) renders the cortisol levels unphysiological, which may cause symptoms and long-term complications. Glucocorticoid replacement is technically feasible by continuous subcutaneous hydrocortisone infusion (CSHI), and can mimic the normal diurnal cortisol rhythm. This method was recently applied to treat a patient through a critical phase of puberty. This is a clinical trial aiming to evaluate CSHI treatment in patients with CAH. The main objective is to determine the effects of CSHI on metabolic parameters (androstenedione and 17-hydroxyprogesterone profiles, and testosterone,adrenocorticotropic hormone(ACTH), cortisol, and bone markers), and to determine the required glucocorticoid doses. Secondary objectives are to determine effects on clinical status, body weight, blood pressure and other metabolic parameters, as well as on subjective health status (AddiQoL, SF36). |
| NCT01843530 ↗ | Randomized, Double-blind, Two Arms, Multicenter, Phase III Study of Berinert for Treatment of ACE Induced Angioedema | Completed | Technische Universität München | Phase 3 | 2013-11-01 | This trial is a randomized, double-blind, two arms, multicenter, Phase III study of Berinert for treatment of ACE induced Angioedema. This study should show that Berinert shortens the time to complete resolution of signs and symptoms of acute ACE-induced angioedema of the upper airway tract compared to placebo when given on top of standard treatment. This study should also compare the time to onset of relief as defined by an at least one point reduction on the severity scale of ACE-induced angioedema with Berinert versus placebo. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for cortisone acetate
Condition Name
Clinical Trial Locations for cortisone acetate
Trials by Country
Clinical Trial Progress for cortisone acetate
Clinical Trial Phase
Clinical Trial Sponsors for cortisone acetate
Sponsor Name
